KR20220028150A - 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 - Google Patents
항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 Download PDFInfo
- Publication number
- KR20220028150A KR20220028150A KR1020227005469A KR20227005469A KR20220028150A KR 20220028150 A KR20220028150 A KR 20220028150A KR 1020227005469 A KR1020227005469 A KR 1020227005469A KR 20227005469 A KR20227005469 A KR 20227005469A KR 20220028150 A KR20220028150 A KR 20220028150A
- Authority
- KR
- South Korea
- Prior art keywords
- bdca2
- seq
- binding fragment
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020247007023A KR20240033168A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 | |
| US62/328,959 | 2016-04-28 | ||
| KR1020187034043A KR102366547B1 (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| PCT/US2017/029802 WO2017189827A1 (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187034043A Division KR102366547B1 (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007023A Division KR20240033168A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220028150A true KR20220028150A (ko) | 2022-03-08 |
Family
ID=58672794
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227005469A Ceased KR20220028150A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020247007023A Ceased KR20240033168A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020187034043A Active KR102366547B1 (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020247035142A Ceased KR20240159012A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020257018429A Pending KR20250088784A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007023A Ceased KR20240033168A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020187034043A Active KR102366547B1 (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020247035142A Ceased KR20240159012A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
| KR1020257018429A Pending KR20250088784A (ko) | 2016-04-28 | 2017-04-27 | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 |
Country Status (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023017936A1 (ko) | 2021-08-09 | 2023-02-16 | 주식회사 인벤테라제약 | 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49962A (fr) * | 2017-08-22 | 2020-07-01 | Biogen Ma Inc | Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé |
| ES3014697T3 (en) | 2018-07-19 | 2025-04-24 | Ichnos Sciences S A | Liquid antibody formulation |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| CN116963716A (zh) * | 2020-12-03 | 2023-10-27 | 渤健马萨诸塞州股份有限公司 | 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥(蘇州)有限公司 | 抗bdca2抗體及其用途 |
| WO2024140838A1 (zh) * | 2022-12-28 | 2024-07-04 | 映恩生物制药(苏州)有限公司 | 抗bdca2抗体-药物偶联物及其用途 |
| IL327431A (en) * | 2023-09-28 | 2026-05-01 | Nanjing Leads Biolabs Co Ltd | BDCA2 monoclonal antibody, fusion protein consisting of the same antibody and TACI and method and use thereof |
| WO2026008012A1 (zh) * | 2024-07-04 | 2026-01-08 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其用途 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| BR122020023058B1 (pt) | 2012-12-10 | 2023-12-05 | Biogen Ma Inc | Ácido nucleico isolado ou ácidos nucleicos |
-
2017
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Ceased
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Ceased
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en not_active Ceased
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 IL IL262514A patent/IL262514B2/en unknown
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active Active
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 KR KR1020247035142A patent/KR20240159012A/ko not_active Ceased
- 2017-04-27 KR KR1020257018429A patent/KR20250088784A/ko active Pending
-
2018
- 2018-10-23 MX MX2025000037A patent/MX2025000037A/es unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
-
2025
- 2025-02-21 US US19/060,474 patent/US20250289895A1/en active Pending
- 2025-06-17 IL IL321561A patent/IL321561A/en unknown
-
2026
- 2026-03-16 JP JP2026042524A patent/JP2026094462A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023017936A1 (ko) | 2021-08-09 | 2023-02-16 | 주식회사 인벤테라제약 | 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102366547B1 (ko) | 항-혈액 수지상 세포 항원 2 항체의 임상적 사용을 위한 약제학적 조성물 및 투약 요법 | |
| JP6949718B2 (ja) | 抗pd−1抗体と他の抗体の組み合わせを含む組成物 | |
| US20220056135A1 (en) | Bifunctional anti-pd-1/sirpa molecule | |
| KR20210030366A (ko) | 항-pd-1 항체 및 이의 용도 | |
| US20220195061A1 (en) | Anti-cd40 antibodies for use in treatment of tidm and insulitis | |
| EP4095158A1 (en) | Pharmaceutical composition containing anti-btla antibody and use thereof | |
| AU2021272212A1 (en) | Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof | |
| CN112804989A (zh) | 抗fgfr2抗体制剂 | |
| JP2025512032A (ja) | Pd-1抗体を含有する安定した高濃度アルギニン製剤及びその使用方法 | |
| AU2024282654A1 (en) | Alpha4beta7 integrin antibody compositions and methods of use | |
| JP2025519612A (ja) | Igf1r抗体 | |
| EP4536280A2 (en) | Anti-igf-1r antibody compositions | |
| TW202222829A (zh) | 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法 | |
| WO2025098341A1 (en) | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF | |
| BR122024003611A2 (pt) | Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba | |
| BR112018072125B1 (pt) | Composição farmacêutica e seringa, injetor ou bomba | |
| EA053327B1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| EA043069B1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| JP2025512031A (ja) | Pd-1抗体を含有する安定した高濃度塩化ナトリウム製剤及びその使用方法 | |
| HK40052955A (zh) | 抗fgfr2抗体制剂 | |
| JP2022524814A (ja) | 抗lingo-1抗体を含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220217 Application number text: 1020187034043 Filing date: 20181123 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220310 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220317 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230420 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220317 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| E601 | Decision to refuse application | ||
| E801 | Decision on dismissal of amendment | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20231004 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20220317 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20231004 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20230919 |